FDA Awards 15 Grants to Stimulate Drug, Device Development for Rare Diseases - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Awards 15 Grants to Stimulate Drug, Device Development for Rare Diseases


The US Food and Drug Administration has awarded 15 grants totaling more than $14 million to boost the development of products for patients with rare diseases.

A panel of outside experts with experience in the disease-related fields reviewed applications for the grants, which will be administered through the FDA’s Orphan Products Grants Program. The grant recipients are:

  • Leonide Saad, Alkeus Pharmaceuticals, Inc., Phase 1 Study of ALK001 for the Treatment of Stargardt Disease—about $167,000 for one year 
  • Parinda Mehta, Children’s Hospital Medical Center Cincinnati, Phase 1 Study of Quercetin for the Treatment of Fanconi Anemia—$600,000 over three years
  • Diva De Leon, Children’s Hospital of Philadelphia, Phase 2A Study of Exendin for the Treatment of Congenital Hyperinsulinism—about $759,000 over three years
  • Soma Jyonouchi, Children’s Hospital of Philadelphia, Phase 1 Study of IL-2 for the Treatment of Wiskott-Aldrich Syndrome—$600,000 over three years
  • Dwight Koeberl, Duke University, Phase 1/2 Study of Clenbuterol for the Treatment of Pompe Disease—$400,000 over two years
  • Leslie Kean, Emory University, Phase 2 Study of Abatacept combined with Calcineurin Inhibition and Methotrexate for Prophylaxis of Graft versus Host Disease—about $1.6 million over four years
  • Todd Levine, PNA Center for Neurological Research, Phase 2B Study of Memantine for the Treatment of Amyotrophic Lateral Sclerosis—about $990,000 over three years
  • Joseph Reynolds, Spineform LLC, Phase 2 Study of the HemiBridge System for the Treatment of Idiopathic Scoliosis—$1.6 million over four years
  • Jonathan Davis, Tufts Medical Center, Phase 2 Study of rhCC10 to Prevent Neonatal Bronchopulmonary Dysplasia—about $1.6 million over four years
  • Glenn Furuta, University of Colorado Denver, Phase 2 Study of Esophageal String Test in Diagnosing Eosinophilic Esophagitis—about $400,000 over two years
  • Johan Van Hove, University of Colorado Denver, Phase 1/2 Study of Taurine for the Treatment of Cystathionine Beta-Synthase Deficient Homocystinuria—about $400,000 over two years
  • Laurence Cooper, University Of Texas MD Anderson Cancer Center, Phase 1 Study of Umbilical Cord Blood Derived CD19 Specific T cell Therapy in the Treatment of Advanced B Cell Malignancies—$600,000 over three years
  • Karl Anderson, University of Texas Medical Branch Galveston, Phase 2 Study of Hemin for the Treatment and Prevention of Porphyria Attacks—about $1.5 million over four years
  • Christopher Goss, University of Washington, Phase 2 Study of Intravenous Gallium Nitrate for the Treatment of Cystic Fibrosis—about $1.6 million over four years
  • Michael Debaun, Vanderbilt University, Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia—about $1.59 million over four years

The FDA’s Orphan Products Grants Program was created by the Orphan Drug Act to promote the development of products for rare diseases. Since its inception, the program has given more than $300 million to fund more than 530 new clinical studies developing treatments for rare diseases and has been used to bring 50 products to marketing approval.

Source: FDA

 

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here